ARS Pharmaceuticals, Inc. — Director's Dealing 2022

Feb 2, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Silverback Therapeutics, Inc. (SBTX)
CIK: 0001671858
Period of Report: 2022-02-01

Reporting Person: Shawver Laura (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-02-01	Common Stock	A	27500	$0.00	Acquired	107395	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-01	Stock Option (right to buy)	$4.85	A	165000	Acquired	2032-01-31	Common Stock (165000)	Direct
2022-02-01	Stock Option (right to buy)	$4.85	A	104500	Acquired	2032-01-31	Common Stock (104500)	Direct

Footnotes

F1: The shares being reported are being issued pursuant to restricted stock units, each one of which represents a contingent right to receive one share of the Issuer's common stock.

F2: Includes 682 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2021.

F3: The shares subject to the option vest in equal monthly installments over the 48 months following February 1, 2022.

F4: 25% of the shares subject to the option vest on February 1, 2023, and the remaining shares will vest monthly thereafter over three years.